NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2017
BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2017

Summary

According to the recently published report 'NADPH Oxidase 4 - Pipeline Review, H2 2017'; NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - NADPH oxidase 4 is an enzyme belonging to NOX family of NADPH oxidases. NADPH Oxidase 4 is localized to non-phagocytic cells where it acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species. So formed ROS have been implicated in numerous biological functions including signal transduction, cell differentiation and tumor cell growth.

The report 'NADPH Oxidase 4 - Pipeline Review, H2 2017' outlays comprehensive information on the NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Genito Urinary System And Sex Hormones, Gastrointestinal, Immunology, Oncology, Respiratory and Undisclosed which include indications Diabetic Complications, Diabetic Nephropathy, Acute Ischemic Stroke, Atherosclerosis, Idiopathic Pulmonary Fibrosis, Ischemia Reperfusion Injury, Ischemic Stroke, Kidney Disease, Kidney Fibrosis, Liver Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)
- The report reviews NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics and enlists all their major and minor projects

- The report assesses NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Additional Details

Publisher : Global Markets Direct
Reference : GMDHC1066TDB
Number of Pages : 43
Report Format : PDF
Table Of Contents for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2017

- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Overview
- NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Companies Involved in Therapeutics Development
- Bioasis Technologies Inc
- GenKyoTex SA
- Glucox Biotech AB
- NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Drug Profiles
- Antisense Oligonucleotides to Inhibit NOX4 for Unspecified Indication - Drug Profile
- Mechanism Of Action
- R&D Progress
- GKT-136901 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GKT-831 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MTfp-siRNA - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit NOX-4 and NOX-2 for Cardiovascular Diseases - Drug Profile
- Small Molecules to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
- Small Molecules to Inhibit NOX-4 for Type-2 Diabetes - Drug Profile
- NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Dormant Products
- Product Development Milestones
- Featured News & Press Releases
  - Aug 03, 2017: Genkyotex's GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated Fibroblasts
  - Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
  - May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis
  - Nov 29, 2015: biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
  - Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis
  - Sep 09, 2015: Genkyotex Announces Top-Line Results of Phase 2 Clinical Program
  - Jul 30, 2015: Genkyotex's NOX1&4 Inhibitor Strategy in Liver Fibrosis Supported by New Preclinical Results
  - Apr 21, 2015: biOasis European Patent Granted for The Use of Transcend for the Delivery of Enzymes to Treat Lysosomal Storage Disease
  - Mar 16, 2015: biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score
  - Nov 13, 2014: Genkyotex Completes Enrollment into Phase 2 Trial of NOX1&4 Inhibitor GKT137831 in Diabetic Nephropathy
  - Apr 10, 2014: Genkyotex's GKT137831 Found to Reverse Fibrosis and Improve Survival in a Model of Persistent Lung Fibrosis
  - Nov 11, 2013: Genkyotex NOX Inhibitor GKT137831 Successfully Shown to Halt Diabetic Kidney Disease
  - Nov 05, 2013: Genkyotex Initiates Multinational Phase II Study with First in Class NOX Inhibitor GKT137831 in Diabetic Nephropathy Patients
  - Oct 21, 2013: Genkyotex Collaborators Elucidate Role of NOX4 in Osteoporosis
  - Sep 09, 2013: Genkyotex Receives FDA IND Approval for Phase II Clinical Study with First in Class NOX Inhibitor GKT137831
  - Appendix
  - Methodology
  - Coverage
  - Secondary Research
  - Primary Research
  - Expert Panel Validation
  - Contact Us

Disclaimer
How to Buy...

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2017

**Option 1 - Online**
Go to our website and pay online with any major debit or credit card:

https://www.bioportfolio.co.uk/product/139755

**Option 2 - Request a Proforma Invoice**
Fill in the details below, and Scan this page and email it to us at bioportfolio97@gmail.com. We will send you a Proforma Invoice and deliver your report on settlement.

- **Your Name:**
- **Job Title:**
- **Your Email:**
- **Your Contact Phone:**
- **Company Name:**
- **Address:**
- **Post/Zip Code:**
- **Country:**
- **P.O. Number:**
- **Any Other Instructions:**

**Pricing Options:** (please tick one)
- $2975 | Single User Price
- $5950 | Site License Price
- $8925 | Enterprise License Price

**Payment Options:** (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

**Authorising Signature:**

**Option 3 - Phone Us on +44 (0)7887 945155**
We will be delighted to give you our personal attention.